Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that the Company has granted a total of 3,261,577 options to purchase
Motif Bio plc LON:MTFB, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, yesterday announced its maiden full year audited financial results as an AIM-listed company. Operational highlights of
Dr Gary Waanders at Healthcare Director at Zeus Capital chats with DirectorsTalk about Motif Bio Plc (LON:MTFB) it’s lead product iclaprim, why it’s special, the trials, what it might achieve
Northland Capital partners view on Motif Bio PLC (LON:MTFB): Motif has met a very aggressive timetable since listing on AIM last year. The company continues to rapidly progress iclaprim towards
Zeus Capital analyst Dr Gary Waanders said this morning about Motif Bio Plc (LON:MTFB): “We believe the current market cap of £44m ($63m) heavily discounts Motif relative to a group
Graham Lumsden, CEO of Motif Bio plc LON:MTFB said: “2015 was a transformational year for Motif Bio, with admission to AIM in April, securing capital of GBP23 million (net of
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, will announce its financial results for the year ended 31 December 2015 on Wednesday 20
Graham Lumsden, CEO of Motif Bio LON:MTFB, commented on the appointments: “We are delighted to welcome both Pete and Rajesh to the team. Pete’s experience in capital markets, M&A, and
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that the Company has been selected to present at the 10(th) International
Beaufort Securities view on Motif Bio PLC: The appointment of The Fulford Group, a specialist strategic adviser in the healthcare sector, is an important step towards the commercialisation of iclaprim.
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
